Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Completed · Phase 2 · NCT05997056
Conditions: Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
At a glance
- Research payments reported, 2025
- $1.3M
- U.S. investigators named
- 3
- Sites paid
- 5
- Planned or actual enrollment
- 12
About the trial
- Sponsor
- Aadi Bioscience, Inc.
- Tested
- nab-sirolimus (drug)
- Dates
- Started 2023-10-20; completion 2025-10-03
- Results posted
- Yes
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors
From ClinicalTrials.gov, last updated 2026-08-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Aadi Bioscience, Inc. reported $1.3M in research payments for this study in 2025 (188 payments).
Products named: Fyarro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael Demeure, MD General Surgery · Newport Beach, CA
- Andrew S. Paulson, MD Medical Oncology · Dallas, TX
- Alexandria T. Phan, M.D. Medical Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hoag Memorial Hospital Presbyterian $608,976
- Texas Oncology P.a. $454,771
- Texas Oncology, P.a. $76,370
- Rocky Mountain Cancer Centers, LLP $58,909
- The Medical College of Wisconsin $53,430
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.